Jaideep Thottassery, Lloyd Winberg, Jihan Youssef, Michael Cunningham, Mostafa Z. Badr – 1 February 1992 – A wide variety of compounds, including hypolipidemic drugs, plasticizers and other industrial chemicals, have been found to cause liver enlargement and hepatic peroxisome proliferation by mechanisms that are unclear. Although thyroid and sex hormones have been shown to modulate the hepatic response to these chemicals, the role of adrenal hormones in these phenomena is not clear, and a few studies have produced conflicting data.

Toshiaki Gunji, Nobuo Kawauchi, Shin Ohnishi, Takashi Ishikawa, Hitoshi Nakagama, Takashi Kaneko, Takashi Moriyama, Nobuyuki Matsuhashi, Yoshio Yazaki, Michio Imawari – 1 February 1992 – Twenty‐two patients with hepatocellular carcinoma were treated by a new method of transcatheter arterial chemoembolization using an autologous blood clot as an embolizing agent. All had underlying advanced cirrhosis (14 Child's class B and 8 Child's class C patients). The median follow‐up interval was 11 mo (range = 2 to 30 mo).

Claude Degott, Gérard Feldmann, Dominique Larrey, Anne‐Marie Durand‐Schneider, Didier Grange, Jean‐Pierre Machayekhi, Alain Moreau, François Potet, Jean‐Pierre Benhamou – 1 February 1992 – Drug‐induced acute hepatitis may be followed by prolonged cholestasis despite the withdrawal of the drug. Eight patients suffering from prolonged cholestasis caused by several drugs were investigated with sequential liver biopsies.

Lennox J. Jeffers, Fuad Hasan, Maria de Medina, Rajender Reddy, Talley Parker, Marcelo Silva, Leonardo Mendez, Eugene R. Schiff, Michael Manns, Michael Houghton, Qui‐Lim Choo, George Kuo – 1 February 1992 – Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus in the pathogenesis of this condition in a retrospective serum analysis for antibody to hepatitis C virus in 129 patients with cryptogenic liver disease.

Jorge J. Gumucio, Thomas F. Imperiale, Arthur J. McCullough – 1 February 1992 – Background. The value of beta‐adrenergic‐antagonist drug therapy for the prevention of initial episodes of gastrointestinal bleeding in patients with cirrhosis and esophageal varices is uncertain, both positive and negative study results having been reported.

Harvey J. Alter – 1 February 1992

Luis Sanchez‐Urdazpal, Albert J. Czaja, Bart van Hoek, Ruud A. F. Krom, Russell H. Wiesner – 1 February 1992 – To identify prognostic features and to define the role of liver transplantation in severe autoimmune chronic active hepatitis, findings before and after corticosteroid therapy in 111 patients were correlated with outcome and compared with the findings in 24 patients who had been selected independently for liver transplantation. Patients whose condition deteriorated during corticosteroid treatment were younger (32 ± 3 yr vs.

Nicolas Argy – 1 February 1992

Joan Clària, Wladimiro Jiménez, Josefa Ros, Mónica Asbert, Anna Castro, Vicente Arroyo, Francisca Rivera, Joan Rodés – 1 February 1992 – Nitric oxide is a vasodilator tonically secreted by endothelial cells that is involved in the regulation of arteriolar tone. This study, which includes two protocols, was performed to investigate whether nitric oxide plays a role in the pathogenesis of arterial hypotension in cirrhosis with ascites.

James H. Kelly, Tarek Koussayer, Da‐Er He, Maria G. Chong, Thomas A. Shang, Hartwell H. Whisennand, Norman L. Sussman – 1 February 1992 – We have established an improved model of fulminant hepatic failure in dogs. Buthionine sulfoximine is used to inactivate glutathione synthesis, and small increments of acetaminophen are given intravenously to maintain the plasma level at approximately 200 μg/ml for 20 hr. This regimen produces severe liver injury along with many of the features seen in humans with acetaminophen poisoning. The first sign of impending liver failure is hypoglycemia.